Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
901-920 of 2,120 trials

Tick-Borne Encephalitis: Novel Cytokine Release Assay

We are studying a new test to measure immune responses to Tick-Borne Encephalitis in healthy and immunosuppressed individuals. This research aims to improve understanding of how well the immune system responds to the virus and vaccination.

Tick-borne Encephalitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyInfectious Diseases

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

HIV and Hepatitis B: Bepirovirsen Treatment Study

We are studying a new treatment for people living with both HIV and chronic Hepatitis B. The trial aims to see if bepirovirsen can help reduce the Hepatitis B virus in patients already receiving antiretroviral therapy.

Hepatitis B1-2 yearsEfficacy phase (II)Investigational MedicinesInfectious DiseasesInternal Medicine

Ovarian and Breast Cancer: zAvatar Test Study

We are exploring whether the zAvatar test can help guide treatment decisions for patients with relapsed ovarian cancer and metastatic breast cancer. This study compares outcomes from the zAvatar test approach to standard care.

Breast CancerOvarian CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan Study

We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.

Esophageal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Psoriasis Management: Proactive Drug Monitoring Study

We are comparing proactive drug monitoring to standard care for people with moderate to severe psoriasis. The goal is to see if proactive monitoring helps maintain better disease control and improves quality of life.

Moderate-to-Severe Psoriasis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyDermatology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Sepsis Treatment: Meropenem vs. Piperacillin/Tazobactam

We are comparing two antibiotics to see which one may help critically ill adults with sepsis survive better and improve their health outcomes.

Septic ShockSepsis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Narsoplimab for Children with High-Risk Stem Cell Transplant Complications

We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.

Thrombotic Microangiopathy1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyHematologyInternal Medicine

CART Cell Therapy for Acute Lymphoblastic Leukemia in Young Patients

We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.

Acute Lymphoblastic Leukemia (ALL)>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Pulmonary Aspergillosis: MIRAGE Imaging Study

We are testing a new imaging method using a radioactive substance to see if it helps visualize lung infections caused by Aspergillus. This study aims to improve diagnosis and understanding of this condition.

Pulmonary AspergillosisEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology